Cytoreductive treatment in patients with CALR‐mutated essential thrombocythaemia: a study comparing indications and efficacy among genotypes from the Spanish Registry of Essential Thrombocythaemia

The present study assessed the criteria for initiating cytoreduction and response to conventional therapies in 1446 patients with essential thrombocythemia (ET), 267 (17%) of which were CALR‐mutated. In low risk patients, time from diagnosis to cytoreduction was shorter in CALR‐positive than in the...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	British journal of haematology 2021-03, Vol.192 (6), p.988-996
Hauptverfasser:	Alvarez‐Larrán, Alberto, Angona, Anna, Andrade‐Campos, Marcio, Soledad Noya, M., Teresa Gómez‐Casares, M., Cuevas, Beatriz, Caballero, Gonzalo, García‐Hernández, Carmen, García‐Gutiérrez, Valentín, Palomino, Alicia, Ferrer‐Marín, Francisca, Isabel Mata‐Vázquez, M., Moretó, Ana, Magro, Elena, Murillo, Ilda, Manuel Alonso‐Domínguez, Juan, María Guerra, José, Guerrero, Lucía, María Raya, José, Pérez‐Encinas, Manuel, Carreño‐Tarragona, Gonzalo, Fox, Laura, Pastor‐Galán, Irene, Bellosillo, Beatriz, Hernández‐Boluda, Juan Carlos
Format:	Artikel
Sprache:	eng
Schlagworte:	calreticulin mutation essential thrombocythaemia genotype Genotypes haematological response Hematology Hydroxyurea Intolerance myeloproliferative neoplasms Risk groups therapy
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Beschreibung
Zusammenfassung:	The present study assessed the criteria for initiating cytoreduction and response to conventional therapies in 1446 patients with essential thrombocythemia (ET), 267 (17%) of which were CALR‐mutated. In low risk patients, time from diagnosis to cytoreduction was shorter in CALR‐positive than in the other genotypes (2·8, 3·2, 7·4 and 12·5 years for CALR, MPL, JAK2V617F and TN, respectively, P
ISSN:	0007-1048 1365-2141
DOI:	10.1111/bjh.16988